UCP1 and metabolic disease: In muscle cells, UCP1 enhances mitochondrial biogenesis and functions in skeletal muscle; targeting UCP1 pharmacologically (e.g., with β3-adrenergic agonists or cold exposure) is an area of interest for combating obesity and metabolic diseases in individuals who are unable to exercise.